Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Michael I. Carr"'
Autor:
Eric Haines, Yuki Nishida, Michael I. Carr, Rafael Heinz Montoya, Lauren B. Ostermann, Weiguo Zhang, Frank T. Zenke, Andree Blaukat, Michael Andreeff, Lyubomir T. Vassilev
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-14 (2021)
Abstract Peposertib (M3814) is a potent and selective DNA-PK inhibitor in early clinical development. It effectively blocks non-homologous end-joining repair of DNA double-strand breaks (DSB) and strongly potentiates the antitumor effect of ionizing
Externí odkaz:
https://doaj.org/article/36b7c6a88d6e4d8b9b33159cd731cb9e
Autor:
Michael I. Carr, Astrid Zimmermann, Li-Ya Chiu, Frank T. Zenke, Andree Blaukat, Lyubomir T. Vassilev
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Despite significant advances in the treatment of acute myeloid leukemia (AML) the long-term prognosis remains relatively poor and there is an urgent need for improved therapies with increased potency and tumor selectivity. Mylotarg is the first AML-t
Externí odkaz:
https://doaj.org/article/0152d81377b3456d9408d315fa043a75
Publikováno v:
Cell Reports, Vol 16, Iss 10, Pp 2618-2629 (2016)
ATM phosphorylation of Mdm2-S394 is required for robust p53 stabilization and activation in DNA-damaged cells. We have now utilized Mdm2S394A knockin mice to determine that phosphorylation of Mdm2-S394 regulates p53 activity and the DNA damage respon
Externí odkaz:
https://doaj.org/article/2d4b5fef1f84435eb3b8a25a6d46ae26
Autor:
Lyubomir T. Vassilev, Andree Blaukat, Frank T. Zenke, Frank Czauderna, Qing Sun, Yan Lan, Bo Marelli, Jin Qi, Guozhong Qin, Huakui Yu, Adam S. Lazorchak, Chunxiao Xu, Yige Guo, Li-Ya Chiu, Michael I. Carr
Supplementary Figure from DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18c2acc1536fcc02da749b1d44d21c68
https://doi.org/10.1158/1541-7786.22528214.v1
https://doi.org/10.1158/1541-7786.22528214.v1
Autor:
Lyubomir T. Vassilev, Andree Blaukat, Frank T. Zenke, Michael I. Carr, Frank Czauderna, Xiaohong Liu, Yige Guo, Qing Sun
Text file with figure legends and two references cited in Fig S6 legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b0029fe928fe2ade375e1222efc5fa0
https://doi.org/10.1158/1541-7786.22512480
https://doi.org/10.1158/1541-7786.22512480
Autor:
Lyubomir T. Vassilev, Andree Blaukat, Frank T. Zenke, Michael I. Carr, Frank Czauderna, Xiaohong Liu, Yige Guo, Qing Sun
Figure S1. Inhibition of DNA-PK activity by M3814 overactivates the p53 response to radiation-induced DSBs. Figure S2. The inactive M3814 enantiomer, M3814R, does not enhance the p53 response to IR and M3814. Figure S3. IR plus M3814 treatment induce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cb092786ed66bf408fcc5a5d70db59a
https://doi.org/10.1158/1541-7786.22512477.v1
https://doi.org/10.1158/1541-7786.22512477.v1
Autor:
Lyubomir T. Vassilev, Andree Blaukat, Frank T. Zenke, Michael I. Carr, Frank Czauderna, Xiaohong Liu, Yige Guo, Qing Sun
SI Fig. 7 with 4 embedded videos. Please click on arrow to see videos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5488f03e7ceb45f6a3cc71a14ee5453b
https://doi.org/10.1158/1541-7786.22512486
https://doi.org/10.1158/1541-7786.22512486
Autor:
Lyubomir T. Vassilev, Andree Blaukat, Frank T. Zenke, Michael I. Carr, Frank Czauderna, Xiaohong Liu, Yige Guo, Qing Sun
Inhibition of DNA double-strand break (DSB) repair in cancer cells has been proposed as a new therapeutic strategy for potentiating the anticancer effects of radiotherapy. M3814 is a novel, selective pharmacologic inhibitor of the serine/threonine ki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c2da83e39f9174938502d53dc098a38
https://doi.org/10.1158/1541-7786.c.6540252.v1
https://doi.org/10.1158/1541-7786.c.6540252.v1
Autor:
Lyubomir T. Vassilev, Andree Blaukat, Frank T. Zenke, Frank Czauderna, Qing Sun, Yan Lan, Bo Marelli, Jin Qi, Guozhong Qin, Huakui Yu, Adam S. Lazorchak, Chunxiao Xu, Yige Guo, Li-Ya Chiu, Michael I. Carr
Radiotherapy is the most widely used cancer treatment and improvements in its efficacy and safety are highly sought-after. Peposertib (also known as M3814), a potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor, effectively suppresse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0844dbdfe98c4fcd7d969a6bceba5225
https://doi.org/10.1158/1541-7786.c.6545648.v1
https://doi.org/10.1158/1541-7786.c.6545648.v1
Autor:
Michael I. Carr, Li-Ya Chiu, Yige Guo, Chunxiao Xu, Adam S. Lazorchak, Huakui Yu, Guozhong Qin, Jin Qi, Bo Marelli, Yan Lan, Qing Sun, Frank Czauderna, Frank T. Zenke, Andree Blaukat, Lyubomir T. Vassilev
Publikováno v:
Molecular Cancer Research. 20:568-582
Radiotherapy is the most widely used cancer treatment and improvements in its efficacy and safety are highly sought-after. Peposertib (also known as M3814), a potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor, effectively suppresse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de5660da45e621df7a7451ae06932aaa
https://doi.org/10.1158/1541-7786.mcr-21-0612
https://doi.org/10.1158/1541-7786.mcr-21-0612